{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:57:57Z","timestamp":1774015077235,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.2\/263\/46"],"award-info":[{"award-number":["RGP.2\/263\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.critrevonc.2026.105149","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:23:14Z","timestamp":1769214194000},"page":"105149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["TRAIL-functionalized nanoparticles in cancer therapy: Molecular mechanisms and translational opportunities"],"prefix":"10.1016","volume":"219","author":[{"given":"Dasari","family":"Sahithi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urushi","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramasubbamma","family":"Ramaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umme","family":"Hani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garima","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khang Wen","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105149_bib1","unstructured":"[PDF] DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer | Semantic Scholar [WWW Document], n.d."},{"key":"10.1016\/j.critrevonc.2026.105149_bib2","article-title":"Advancements in 5-fluorouracil-Loaded liposomal nanosystems: A comprehensive review on recent innovations in nanomedicine for cancer therapy","volume":"96","author":"Ali","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092511","article-title":"Radioresistance in Glioblastoma and the Development of Radiosensitizers","volume":"12","author":"Ali","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105149_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004828","article-title":"Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects","volume":"5","author":"Allen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105149_bib5","doi-asserted-by":"crossref","unstructured":"Allen, T.M., 2002. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer. https:\/\/doi.org\/10.1038\/nrc903.","DOI":"10.1038\/nrc903"},{"key":"10.1016\/j.critrevonc.2026.105149_bib6","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/acs.molpharmaceut.5b00827","article-title":"In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas","volume":"12","author":"Amjad","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib7","article-title":"Advancements in dendrimer-based drug delivery for combinatorial cancer therapy","volume":"97","author":"Arif","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2026.105149_bib9","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.biomaterials.2011.10.050","article-title":"Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types","volume":"33","author":"Bae","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105149_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nano11020502","article-title":"Grafting trail through either amino or carboxylic groups onto maghemite nanoparticles: Influence on pro-apoptotic efficiency","volume":"11","author":"Belkahla","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.critrevonc.2026.105149_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jin2.55","article-title":"Coupling tumor necrosis factor-related apoptosis-inducing ligand to iron oxide nanoparticles increases its apoptotic activity on HCT116 and HepG2 malignant cells: effect of magnetic core size","volume":"4","author":"Belkahla","year":"2019","journal-title":"J. Interdiscip. Nanomed."},{"key":"10.1016\/j.critrevonc.2026.105149_bib12","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1039\/C7NR01469D","article-title":"TRAIL-NP hybrids for cancer therapy: a review","volume":"9","author":"Belkahla","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.critrevonc.2026.105149_bib13","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.7150\/thno.36320","article-title":"TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia","volume":"9","author":"Belkahla","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105149_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.614290","article-title":"Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy","volume":"11","author":"Bhagwat","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib15","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1021\/mp100298r","article-title":"Targeted Imaging and Therapy of Brain Cancer using Theranostic Nanoparticles","volume":"7","author":"Bhojani","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib16","first-page":"45","article-title":"TRAIL conjugated silver nanoparticle synthesis, characterization and therapeutic effects on HT-29 colon cancer cells","volume":"20","author":"Birtekocak","year":"2021","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.critrevonc.2026.105149_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.critrevonc.2026.105149_bib18","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1021\/acs.molpharmaceut.6b00776","article-title":"Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors","volume":"13","author":"Butt","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120835","article-title":"Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer","volume":"605","author":"Chadar","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112044","article-title":"Carbon nanotubes as an emerging nanocarrier for the delivery of doxorubicin for improved chemotherapy","volume":"208","author":"Chadar","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.critrevonc.2026.105149_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1535-7163.MCT-11-0620","article-title":"A 71-gene signature of TRAIL sensitivity in cancer cells","volume":"11","author":"Chen","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105149_bib22","doi-asserted-by":"crossref","first-page":"22639","DOI":"10.1074\/jbc.M110.125906","article-title":"Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer","volume":"285","author":"Chen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105149_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2014.11.008","article-title":"Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer","volume":"197","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105149_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.05.042","article-title":"Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting","volume":"565","author":"Choudhury","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.04.005","article-title":"Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology","volume":"101","author":"Choudhury","year":"2019","journal-title":"Mater. Sci. Eng. C."},{"key":"10.1016\/j.critrevonc.2026.105149_bib26","article-title":"Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery","volume":"54","author":"Choudhury","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcis.2015.11.054","article-title":"Layer by layer assembly of albumin nanoparticles with selective recognition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)","volume":"465","author":"Cui","year":"2016","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.critrevonc.2026.105149_bib28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.leukres.2015.03.019","article-title":"Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells","volume":"39","author":"De Miguel","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2026.105149_bib29","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1088\/0957-4484\/27\/18\/185101","article-title":"TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells","volume":"27","author":"De Miguel","year":"2016","journal-title":"Nanotechnology"},{"key":"10.1016\/j.critrevonc.2026.105149_bib30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.canlet.2016.10.005","article-title":"High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer","volume":"383","author":"De Miguel","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105149_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.canlet.2016.10.005","article-title":"High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer","volume":"383","author":"De Miguel","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105149_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1574892811666160229121544","article-title":"Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells","volume":"11","author":"De Miguel","year":"2016","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105149_bib33","article-title":"Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of Gemcitabine with natural polysaccharides for treatment of breast cancer","volume":"56","author":"Devi","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib34","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/0008-5472.CAN-08-2747","article-title":"Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP","volume":"69","author":"Dong","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105149_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/09205063.2015.1133155","article-title":"Dendrimer-mediated approaches for the treatment of brain tumor","volume":"27","author":"Dwivedi","year":"2016","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.critrevonc.2026.105149_bib36","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/09205063.2018.1483616","article-title":"Synthesis, characterization, and in vitro evaluation of TRAIL-modified, cabazitaxel -loaded polymeric micelles for achieving synergistic anticancer therapy","volume":"29","author":"Feng","year":"2018","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.critrevonc.2026.105149_bib37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.actbio.2022.03.001","article-title":"TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy","volume":"143","author":"Feng","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2026.105149_bib38","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/S0140-6736(14)61457-4","article-title":"Cancer nanomedicines: closing the translational gap","volume":"384","author":"Gabizon","year":"2014","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.critrevonc.2026.105149_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01849-0","article-title":"Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics","volume":"22","author":"Gajbhiye","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105149_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051449","article-title":"Lipid nanoparticles decorated with TNF-related aptosis-inducing ligand (TRAIL) are more cytotoxic than soluble recombinant TRAIL in sarcoma","volume":"19","author":"Gallego-Lleyda","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105149_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2017.08.036","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data","volume":"409","author":"Gamie","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105149_bib42","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1074\/jbc.M116.754184","article-title":"Bax\/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma","volume":"292","author":"Gillissen","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105149_bib43","first-page":"3705","article-title":"UBE2S targets RPL26 for ubiquitination and degradation to promote non-small cell lung cancer progression via regulating c-Myc","volume":"13","author":"Gong","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105149_bib44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1021\/acsnano.7b05876","article-title":"Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy","volume":"12","author":"Guimar\u00e3es","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105149_bib45","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/onc.2010.599","article-title":"Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation","volume":"30","author":"H\u00e4cker","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105149_bib46","article-title":"Ac ce p te d cr t","author":"Herlem","year":"2015","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.critrevonc.2026.105149_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cytogfr.2013.12.009","article-title":"Death receptor agonist therapies for cancer, which is the right TRAIL?","volume":"25","author":"Holland","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.critrevonc.2026.105149_bib48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/ntno.20233","article-title":"Trail-functionalized gold nanoparticles selectively trigger apoptosis in polarized macrophages","volume":"1","author":"Huang","year":"2017","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.critrevonc.2026.105149_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1097-2765(00)80207-5","article-title":"Triggering Cell Death: The Crystal Structure of Apo2L\/TRAIL in a Complex with Death Receptor 5","volume":"4","author":"Hymowitz","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2026.105149_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101033","article-title":"TRAIL-driven targeting and reversing cervical cancer radioresistance by seleno-nanotherapeutics through regulating cell metabolism","volume":"72","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.critrevonc.2026.105149_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jconrel.2022.07.004","article-title":"TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth","volume":"349","author":"Jun","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105149_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw4197","article-title":"Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection","volume":"5","author":"Jyotsana","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105149_bib53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/B978-0-323-89868-3.00022-7","article-title":"Triblock polymeric micelles as an emerging nanocarrier for drug delivery","author":"Kar","year":"2022","journal-title":"Polym. Micelles Drug Deliv."},{"key":"10.1016\/j.critrevonc.2026.105149_bib54","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jconrel.2021.08.003","article-title":"Advanced nanomedicine approaches applied for treatment of skin carcinoma","volume":"337","author":"Kaur","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105149_bib55","article-title":"Experimental Models for Evaluation of Nanoparticles in Cancer Therapy","volume":"17","author":"Kesharwani","year":"2016","journal-title":"MiniRev. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105149_bib56","doi-asserted-by":"crossref","unstructured":"Kesharwani, P., Ghanghoria, R., Jain, N.K., 2012. Carbon nanotube exploration in cancer cell lines. Drug Discov. Today.","DOI":"10.1016\/j.drudis.2012.05.003"},{"key":"10.1016\/j.critrevonc.2026.105149_bib57","doi-asserted-by":"crossref","unstructured":"Kesharwani, P., Mishra, V., Jain, N.K., 2015. Validating the anticancer potential of carbon nanotube-based therapeutics through cell line testing. Drug Discov. Today. https:\/\/doi.org\/10.1016\/j.drudis.2015.05.004.","DOI":"10.1016\/j.drudis.2015.05.004"},{"key":"10.1016\/j.critrevonc.2026.105149_bib58","unstructured":"Kesharwani, P., Tekade, R.K., Jain, N.K., 2014. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond)."},{"key":"10.1016\/j.critrevonc.2026.105149_bib59","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.drudis.2018.01.021","article-title":"Administration of antioxidants in cancer: debate of the decade","volume":"23","author":"Khurana","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105149_bib60","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1021\/mp900021q","article-title":"In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib61","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.0022-202X.2005.23900.x","article-title":"Efficient TRAIL-R1\/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)","volume":"125","author":"Kurbanov","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105149_bib63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.critrevonc.2026.105149_bib64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2007.08.006","article-title":"Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)","volume":"123","author":"Lee","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105149_bib65","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.critrevonc.2026.105149_bib66","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40880-016-0140-0","article-title":"Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma","volume":"35","author":"Leng","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105149_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.colsurfa.2020.124486","article-title":"Supramolecular assembly of protein-based nanoparticles based on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for cancer therapy","volume":"590","author":"Li","year":"2020","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.critrevonc.2026.105149_bib68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","article-title":"Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis","volume":"94","author":"Li","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105149_bib69","first-page":"399","article-title":"Hesperidin, a plant flavonoid accelerated the cutaneous wound healing in streptozotocin-induced diabetic rats: Role of TGF-\u00df\/Smads and Ang-1\/Tie-2 signaling pathways","volume":"17","author":"Li","year":"2018","journal-title":"EXCLI J."},{"key":"10.1016\/j.critrevonc.2026.105149_bib70","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1016\/j.biomaterials.2011.01.054","article-title":"Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles","volume":"32","author":"Lim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105149_bib71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.biomaterials.2018.05.036","article-title":"Photo-excitable hybrid nanocomposites for image-guided photo\/TRAIL synergistic cancer therapy","volume":"176","author":"Lin","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105149_bib72","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ctrv.2008.11.006","article-title":"TRAIL receptor signalling and modulation: Are we on the right TRAIL?","volume":"35","author":"Mahalingam","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105149_bib73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105149_bib74","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1128\/MCB.00520-06","article-title":"Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2","volume":"26","author":"M\u00e9rino","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib75","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1111\/bph.12238","article-title":"Death receptors as targets in cancer","volume":"169","author":"Micheau","year":"2013","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib76","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrclinonc.2010.98","article-title":"Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma","volume":"7","author":"Morris","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2022.111471","article-title":"Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy","volume":"177","author":"Mukherjee","year":"2022","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.critrevonc.2026.105149_bib78","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/17425247.2023.2223941","article-title":"Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy","volume":"20","author":"Narmani","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.critrevonc.2026.105149_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122733","article-title":"Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer","volume":"312","author":"Nguyen","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105149_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08589-8","article-title":"TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients","volume":"21","author":"Ortiz-Otero","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105149_bib81","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejpb.2021.02.010","article-title":"Recent update of toxicity aspects of nanoparticulate systems for drug delivery","volume":"161","author":"Patnaik","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib82","unstructured":"Perlstein, B., Finniss, S.A., Miller, C., Okhrimenko, H., Kazimirsky, G., Cazacu, S., Lee, H.K., Lemke, N., Brodie, S., Umansky, F., Rempel, S.A., Rosenblum, M., Mikklesen, T., Margel, S., 2012. N E U RO - O N CO LO GY 48202."},{"key":"10.1016\/j.critrevonc.2026.105149_bib83","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1215\/15228517-2008-002","article-title":"Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring","volume":"10","author":"Perlstein","year":"2008","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2172-13-40","article-title":"Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5\/TRAIL complex formation","volume":"13","author":"Qiao","year":"2012","journal-title":"BMC Immunol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib85","article-title":"Applications of carbon nanotube biosensors: Sensing the future","volume":"97","author":"Ranjbari","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib86","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-15-2170","article-title":"TNF-related apoptosis-inducing ligand (trail)-armed exosomes deliver proapoptotic signals to tumor site","volume":"22","author":"Rivoltini","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105149_bib87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.pmbts.2023.12.010","article-title":"Advances in liposome-based delivery of RNA therapeutics for cancer treatment","volume":"204","author":"Sanati","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.critrevonc.2026.105149_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-5-54","article-title":"Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells","volume":"5","author":"Sanlioglu","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105149_bib89","doi-asserted-by":"crossref","first-page":"22532","DOI":"10.1074\/jbc.274.32.22532","article-title":"Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells","volume":"274","author":"Scaffidi","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105149_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2010.45","article-title":"Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins","volume":"1","author":"Schneider","year":"2010","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105149_bib91","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/bc400517j","article-title":"Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles","volume":"25","author":"Seifert","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.critrevonc.2026.105149_bib92","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/bc400517j","article-title":"Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles","volume":"25","author":"Seifert","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.critrevonc.2026.105149_bib93","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1142\/S2339547816500011","article-title":"Two-stage nanoparticle delivery of piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy","volume":"04","author":"Sharkey","year":"2016","journal-title":"Technology"},{"key":"10.1016\/j.critrevonc.2026.105149_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2021.110746","article-title":"An insight into aptamer engineered dendrimer for cancer therapy","volume":"159","author":"Sheikh","year":"2021","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.critrevonc.2026.105149_bib95","first-page":"1","article-title":"Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy","volume":"16","author":"Sheikh","year":"2024","journal-title":"NanoMicro Lett."},{"key":"10.1016\/j.critrevonc.2026.105149_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112530","article-title":"Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer","volume":"146","author":"Sheikh","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105149_bib97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2021.10.028","article-title":"RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy","volume":"340","author":"Sheikh","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105149_bib98","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1016\/j.biomaterials.2014.06.036","article-title":"Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles","volume":"35","author":"Shi","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105149_bib99","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.drudis.2021.03.011","article-title":"The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer","volume":"26","author":"Singh","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105149_bib100","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/sj.onc.1204282","article-title":"Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways","volume":"20","author":"Suliman","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105149_bib101","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.critrevonc.2026.105149_bib102","article-title":"Recent advances in folic acid engineered nanocarriers for treatment of breast cancer","volume":"56","author":"Tagde","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.critrevonc.2026.105149_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2016.06.029","article-title":"RNAi-combined nano-chemotherapeutics to tackle resistant tumors","author":"Tekade","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105149_bib104","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omto.2021.04.004","article-title":"Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer","volume":"21","author":"Vaughan","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.critrevonc.2026.105149_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-03567-1","article-title":"Splicing reprogramming of TRAIL\/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis","volume":"12","author":"Voss","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105149_bib106","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1006\/bbrc.2000.3512","article-title":"Isolation and molecular characterization of the 5\u2019-upstream region of the human TRAIL gene","volume":"276","author":"Wang","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105149_bib107","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1535-6108(04)00113-8","article-title":"Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway","volume":"5","author":"Wang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105149_bib108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1126\/science.1059108","article-title":"Proapoptotic BAX and BAK A Requisite Gateway to Mitochondrial Dysfunction and Death","volume":"292","author":"Wei","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105149_bib109","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1349-7006.2004.tb02181.x","article-title":"TRAIL and its receptors as targets for cancer therapy","volume":"95","author":"Yagita","year":"2004","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105149_bib110","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1080\/10717544.2017.1384863","article-title":"TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors","volume":"24","author":"Yang","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.critrevonc.2026.105149_bib111","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1021\/nl503565t","article-title":"Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing","volume":"15","author":"Zakaria","year":"2015","journal-title":"Nano Lett."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:43:51Z","timestamp":1774007031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":111,"alternative-id":["S1040842826000363"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105149","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRAIL-functionalized nanoparticles in cancer therapy: Molecular mechanisms and translational opportunities","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105149"}}